N/A
Completed N=204
Mindfulness-Based Recovery in Veterans
Substance Abuse · Depression · Anxiety
Source: ClinicalTrials.gov NCT02326363 ↗
Enrolled (actual)
204
Serious AEs
14.2%
Results posted
Jul 2020
Primary outcomePrimary: Timeline Follow-Back (TLFB) - Number of Participants With Alcohol, Illicit Substance and Cigarette Use During Treatment up to 8 Weeks. Available Date — 8; 12; 9; 4 Participants
Summary
This study will provide important information concerning the used of mindfulness-based relapse prevention (MBRP) as a continuing care strategy for Veterans who have completed primary treatment for a SUD. Most research is focused on the acute care of SUDs, but the risk of relapse to substance use is highest during the period immediately following treatment and attention to continuing care is critical. If this trial demonstrates that MBRP promotes sustained abstinence and improved functional outcomes, this will provide a valuable treatment to facilitate rehabilitation and recovery for Veterans with SUDs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Timeline Follow-Back (TLFB) - Number of Participants With Alcohol, Illicit Substance and Cigarette Use During Treatment up to 8 Weeks. Available Date |
8; 12; 9; 4; 46; 62 | — |
| PRIMARY Timeline Follow-Back (TLFB) - Number of Participants With Alcohol, Binge Alcohol, Illicit Drug Use. Available Date |
25; 37; 13; 20; 18; 29 | — |
| PRIMARY Time to Relapse to Substance Use - Days to First Alcohol, Binge Alcohol and Illicit Substance Use. Available Data |
110; 128; 95; 196; 1; 48 | — |
| SECONDARY Mindfulness Acceptance and Awareness Scale (MAAS) |
3.99; 4.12; 4.04; 4.26; 4.10; 4.55 | — |
| SECONDARY Beck Depression Inventory 2 |
15.28; 14.26; 8.96; 7.02; 11.75; 8.93 | — |
| SECONDARY Beck Anxiety Inventory |
14.99; 16.28; 14.94; 11.09; 14.24; 10.46 | — |
| SECONDARY Urine Drug Screen |
0; 0; 1; 3; 2; 2 | — |
| SECONDARY EtG |
4; 9; 3; 1; 2; 1 | — |
| SECONDARY Addiction Severity Index, Lite |
.1186; .1180; .1115; .0877; .0764; .1124 | — |
| SECONDARY Days Engaging in Structured/Productive Work Activities (PWAC) |
1; 0; 0; 0; 2; 0 | — |
| SECONDARY Treatment Engagement: Treatment Attendance Calendar (TAC) |
6; 4; 4; 4; 3; 3 | — |
| SECONDARY Quality of Life Scale (QOLS) is a 16 Item Scale Measuring Quality of Life. |
74; 73; 75; 81; 75; 80 | — |
| SECONDARY Urine Drug Screen - End of Study |
8; 6; 10; 7; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Men and women military Veterans who have completed the Charleston or Tuscaloosa Veterans Administration Medical Center (VAMC) intensive outpatient substance abuse treatment program, a residential treatment program, or an intensive outpatient program similar to the Charleston or Tuscaloosa VAMC program.
- Able to comprehend English.
- Meets DSM-V criteria for a current substance use disorder and have used substances in the 30 days prior to treatment entry. Participants on medications targeting their substance use must be stabilized on medications for at least 2 weeks before therapy initiation.
- May meet criteria for a mood, anxiety or other psychiatric disorder. Participants on maintenance medications for a mood or anxiety disorder must be stabilized on medications for at least 2 weeks before therapy initiation.
- Able to adequately provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
- Willing to commit to 8 group therapy sessions, baseline, weekly and follow-up assessments for 10-months after the end of treatment (12-month total).
Exclusion Criteria
- Active suicidal or homicidal ideation with a plan as this is likely to require hospitalization or other interventions that could interfere with study participation.
- Unstable psychiatric condition likely to require hospitalization or other interventions that would interfere with study participation.
- Unstable medical condition or one that may require hospitalization during the course of the study.
- Meets criteria for nicotine dependence only
- Women who are pregnant
Data sourced from ClinicalTrials.gov (NCT02326363). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.